Teva Pharmaceutical Industries continues to impress investors with strong sales growth and promising development. Click here ...

Vedolizumab prevented the postoperative recurrence of Crohn’s disease and should be considered a prophylactic treatment in ...

During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the ...

Ustekinumab-stba, manufactured by Celltrion, is expected to be marketed in the United States in February 2025.

Teva Pharmaceutical (NYSE:TEVA) and Sanofi (NASDAQ:SNY) stocks were rising on Tuesday after the companies announced successful results of a phase 2 study involving the treatment of patients with ...

Your belly button could hurt for various reasons, some involving nearby organs. The pain might stem from acute (short-lived) issues like constipation or indigestion. Serious causes could include ...

Teva Pharmaceuticals and Sanofi announced positive results in a Phase 2b trial of their drug for ulcerative colitis and Crohn ...

took off Tuesday after the two drugmakers reported positive results from a study of their treatment for ulcerative colitis (UC) and Crohn’s disease. A press release from Teva on Tuesday said the ...

Sanofi and Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd., today announced that the RELIEVE UCCD phase 2b study met its primary endpoints in patients with ulcerative ...

We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally ... our ability to successfully develop duvakitug for the treatment of ...